Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study

Back

EHRA Premium Access

Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study

Session: Prevention of stroke in atrial fibrillation

Topic: Oral Anticoagulation

Speaker: Professor J. De Groot (Amsterdam, NL)

Event: EHRA 2021

Congress Presentation

About the speaker

Professor Joris R De Groot

Amsterdam University Medical Centre, Amsterdam (Netherlands (The))

15 presentations

3 followers

6 more presentations in this session

Contemporary data evaluating 1-year clinical outcomes in patients with atrial fibrillation and coexisting valvular heart disease: the ETNA-AF-Europe study

Speaker: Professor F. Ricci (Chieti, IT)

Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe

Speaker: Professor T. de Vries (Amsterdam, NL)

Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation

Speaker: Doctor S. Lee (Seoul, KR)

Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF

Speaker: Doctor D. Morrone (Pisa, IT)

Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program

Speaker: Doctor L. Dinshaw (Wismar, DE)

Access the full session

Prevention of stroke in atrial fibrillation

Speakers: Professor J. De Groot, Professor F. Ricci, Professor T. de Vries, Doctor S. Lee, Doctor D. Morrone...

Access

About the event

EHRA 2021

23 April - 25 April 2021

Sessions Presentations

Congress

Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study

About the speaker

Professor Joris R De Groot

6 more presentations in this session

Contemporary data evaluating 1-year clinical outcomes in patients with atrial fibrillation and coexisting valvular heart disease: the ETNA-AF-Europe study

Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe

Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation

Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF

Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program

Access the full session

Prevention of stroke in atrial fibrillation

About the event

EHRA 2021

ESC 365 is supported by